Takeda: cross-border access for the specialty portfolio

Quick orientation

Takeda Pharmaceutical Company Limited is a Japanese multinational headquartered in Osaka with US operations centered in Cambridge, Massachusetts. The 2019 acquisition of Shire substantially expanded Takeda's rare-disease, hematology, and immunology footprint. Takeda's specialty footprint is anchored in gastroenterology (Entyvio for IBD), hematology and rare disease (Adynovate, Advate; Takhzyro and the HAE franchise; Vpriv and Elaprase in lysosomal storage diseases), oncology (Alunbrig in ALK-positive NSCLC; Adcetris co-marketed with Pfizer; Iclusig in CML), and neuroscience.

Portfolio in cross-border NPP scope

Entyvio (vedolizumab)

Anti-alpha-4-beta-7-integrin monoclonal antibody approved for moderately to severely active ulcerative colitis and Crohn's disease, with both IV and subcutaneous formulations approved. International requests cluster around IBD patients in the Gulf and India who want the subcutaneous maintenance formulation where local supply is limited to the IV form.

Takhzyro (lanadelumab)

Plasma kallikrein inhibitor monoclonal antibody approved for prophylaxis of hereditary angioedema attacks in patients 2 and older. International requests come from HAE patients in MENA and India who have failed C1 inhibitor concentrate prophylaxis or who prefer the every-two-weeks subcutaneous schedule.

Vpriv (velaglucerase alfa)

Recombinant beta-glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease. Cross-border requests come from Gaucher patients in MENA and India where the locally available enzyme replacement supply has been intermittent.

Elaprase (idursulfase)

Enzyme replacement therapy for Hunter syndrome (MPS-II). International requests come from MPS-II pediatric patients in MENA and India, populations where consanguinity-driven prevalence is significant.

Adynovate and Advate

Recombinant antihemophilic factor VIII products. Adynovate is the PEGylated extended-half-life version; Advate is the standard half-life. Cross-border requests come from hemophilia A centers in MENA and India.

Alunbrig (brigatinib)

ALK inhibitor approved for ALK-positive metastatic NSCLC. International requests come from ALK-positive NSCLC patients in MENA and India who have failed first or second-generation ALK inhibitors.

Iclusig (ponatinib)

Pan-BCR-ABL TKI approved for chronic-phase CML and Ph-positive ALL after failure of two or more prior TKIs. International requests come from heavily-treated CML and Ph-positive ALL patients where the T315I-mutation salvage option is needed.

Vyvanse, Mydayis (controlled substances, out of scope)

Schedule II stimulants for ADHD and binge eating disorder. Reserve Meds does not coordinate Vyvanse or Mydayis cross-border (consistent with our no-controlled-substances policy).

Hyqvia and Cuvitru

Subcutaneous immunoglobulin replacement products for primary immunodeficiency and CIDP. International requests come from PI patients in MENA and India who prefer the subcutaneous home-administered route over IVIG hospital infusion.

Why patients route Takeda products through cross-border NPP

Three patterns dominate. First, the Shire-origin lysosomal storage disease franchise (Vpriv, Elaprase) operates at very small patient populations where local registration and supply reliability vary. Second, the HAE franchise (Takhzyro) has a higher prevalence-relative-to-locally-registered-options gap in MENA and India where consanguinity contributes to disease cluster patterns. Third, Entyvio subcutaneous and pediatric weight-banded IBD presentations are typical local-launch lag cases. The Takeda Patient Assistance Program is restricted to US residents.

Manufacturer engagement posture

Reserve Meds coordinates Takeda and Shire-origin US product through DSCSA-compliant specialty wholesaler channels. We are not an authorized Takeda distributor. We do not coordinate controlled substances. All Reserve Meds orders are cash-pay at firm-quote pricing.

For Takeda market access teams: Reserve Meds maintains structured demand visibility across rare-disease, hematology, IBD, and oncology franchises. If your group is sizing pre-registration demand in MENA and India for the rare-disease franchise specifically, we are open to a structured conversation under NDA.

Common cross-border destinations for the Takeda portfolio

The lysosomal storage disease franchise (Vpriv, Elaprase) concentrates in tertiary metabolic disease centers in the UAE, Saudi Arabia, India, Egypt, and Kuwait. The HAE franchise (Takhzyro) is heaviest in Saudi Arabia and the Gulf. The IBD franchise (Entyvio) is broad across the Gulf and India. The hemophilia franchise tracks established hemophilia centers across MENA and India.

What Reserve Meds provides

For every Takeda product order, Reserve Meds coordinates DSCSA chain-of-custody documentation; cold-chain validated logistics where required; country regulatory pathway expertise covering named-patient import approval, customs clearance, and any required physician declaration; and a single patient-facing coordinator. We do not replace the patient's treating physician. A US-licensed pharmacist reviews every prescription before dispensing.

Next step for patients

Patients or caregivers who have a treating physician's prescription for a Takeda product and want a firm quote can start a request below.

Start a request for a Takeda product

Next step for Takeda teams

If you are on the Takeda access, medical affairs, or international market access team and want to discuss coordinated named-patient program demand from MENA and India, reach us at [email protected]. We will share aggregated demand views under NDA.

Reserved for you.